CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Short Interest Down 32.7% in August

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) was the target of a significant decline in short interest in August. As of August 14th, there was short interest totaling 219,694 shares, a decline of 32.7% from the July 30th total of 326,576 shares. Based on an average trading volume of 154,457 shares, the short-interest ratio is currently 1.4 days. Currently, 0.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CSLLY. Canaccord Genuity Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Jefferies Financial Group cut CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Finally, Citigroup downgraded CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Five analysts have rated the stock with a Hold rating, Based on data from MarketBeat, CSL currently has an average rating of “Hold”.

CSL Price Performance

Shares of CSL stock opened at $30.56 on Tuesday. The stock has a 50 day moving average of $23.45 and a 200 day moving average of $25.22. CSL has a 12 month low of $16.01 and a 12 month high of $36.28. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.